Pathophysiology, Therapeutic Targets, and Future Therapeutic Alternatives in COPD: Focus on the Importance of the Cholinergic System

Abstract

Chronic obstructive pulmonary disease (COPD) is a progressive disease characterized by airway limitation and changes in airway structure. It has a high global burden of mortality and morbidity. The etiology of COPD is complex, but exposure to tobacco smoke and other inhaled lung oxidants are major risk factors. Both pharmacological and non-pharmacological approaches are used to manage COPD, but there remains an urgent unmet need for drugs that can modify the course of the disease. This review focuses on the role of acetylcholine and other components of the pulmonary cholinergic system in the pathogenesis of COPD, and the inhaled pharmacological agents that target it. In addition to its role as a neurotransmitter, acetylcholine regulates diverse aspects of COPD pathogenesis including bronchoconstriction, airway remodeling, mucus secretion and inflammation. Inhaled antimuscarinic drugs are a key component of therapy for COPD, as monotherapy or in combination with inhaled β2 agonists or corticosteroids. We review the evidence supporting the use of current anticholinergic agents in COPD and preview novel drugs targeting the cholinergic system and agents from other classes in clinical development, such as phosphodiesterase-4 inhibitors and monoclonal antibodies targeting inflammatory mediators.

Back to the Basics: Usefulness of Naturally Aged Mouse Models and Immunohistochemical and Quantitative Morphologic Methods in Studying Mechanisms of Lung Aging and Associated Diseases

“…COPD is characterized by airflow limitation that is not fully reversible. Changes present in the lungs of COPD patients vary, but they may include emphysema, chronic bronchitis, and mucociliary dysfunction [99,100]. In 2019, COPD was the third most common cause of death [101].…”

NADH Intraperitoneal Injection Prevents Lung Inflammation in a BALB/C Mice Model of Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease

“…Chronic obstructive pulmonary disease (COPD), a condition that affects 328 million people worldwide, is one of the most frequent and life-threatening non-communicable, preventable, and irreversible chronic lung diseases. The Global Burden of Disease report states that COPD is the third leading cause of death in the world [1,2]. COPD is characterized by chronic inflammation that causes damages to the airways, alveoli, and pulmonary vessels, ultimately leading to airflow limitation [3].…”

New promising agents against COPD and asthma among the amides of 1-oxo-3-phenyl-isochroman-6-carboxylic acid

“…This is because, although it binds to M2 receptors, it dissociates from these significantly faster than from M3 type receptors. Compared to ipratropium, tiotropium bromide has lower oral bioavailability and systemic side effects, and an extended half-life in patient's body [15][16][17]. However, the use of tiotropium bromide for the therapy of stable asthma may be ineffective due to insufficient drug dosage, while increasing the dosage can lead to side effects [1,18].…”